Chemistry:Vosoritide

From HandWiki
Short description: Experimental drug for the treatment of achondroplasia
Vosoritide
Vosoritid.svg
Clinical data
Trade namesVoxzogo
Other namesBMN-111
License data
Pregnancy
category
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC176H290N56O51S3
Molar mass4102.78 g·mol−1
3D model (JSmol)

Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia.[3][4][5]

The most common side effects include injection site reactions (such as swelling, redness, itching, or pain), vomiting, and decreased blood pressure.[3][4][5]

Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth.[4] The average height of an adult with achondroplasia is approximately four feet.[4] People with achondroplasia have a genetic mutation that causes a certain growth regulation gene called fibroblast growth factor receptor 3 to be overly active, which prevents normal bone growth.[4] Vosoritide works by binding to a specific receptor called natriuretic peptide receptor-B that reduces the growth regulation gene's activity and stimulates bone growth.[4]

Vosoritide was approved for medical use in the European Union in August 2021,[5][6][7] and in the United States in November 2021.[4][8] The US Food and Drug Administration considers it to be a first-in-class medication.[9]

Medical uses

In the European Union, vosoritide is indicated for the treatment of achondroplasia in people two years of age and older whose epiphyses are not closed.[5]

In the United States, vosoritide is indicated to increase growth in children five years of age and older with achondroplasia and open epiphyses (growth plates).[3][4]

Mechanism of action

A: Chondrocyte with constitutionally active FGFR3 that down-regulates its development via the MAPK/ERK pathway
B: Vosoritide (BMN 111) blocks this mechanism by binding to the atrial natriuretic peptide receptor B (NPR-B), which subsequently inhibits the MAPK/ERK pathway at the RAF-1 protein.[10]

Vosoritide works by binding to a receptor (target) called natriuretic peptide receptor type B (NPR-B), which reduces the activity of fibroblast growth factor receptor 3 (FGFR3).[5] FGFR3 is a receptor that normally down-regulates cartilage and bone growth when activated by one of the proteins known as acidic and basic fibroblast growth factor. It does so by inhibiting the development (cell proliferation and differentiation) of chondrocytes, the cells that produce and maintain the cartilaginous matrix which is also necessary for bone growth. Children with achondroplasia have one of several possible FGFR3 mutations resulting in constitutive (permanent) activity of this receptor, resulting in overall reduced chondrocyte activity and thus bone growth.[10]

The protein C-type natriuretic peptide (CNP), naturally found in humans, reduces the effects of over-active FGFR3. Vosoritide is a CNP analogue with the same effect but prolonged half-life,[10] allowing for once-daily administration.[11]

Chemistry

Vosoritide is an analog of CNP. It is a peptide consisting of the amino acids proline and glycine plus the 37 C-terminal amino acids from natural human CNP. The complete peptide sequence is

PGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC

with a disulfide bridge between positions 23 and 39 (underlined).[12] The drug must be administered by injection as it would be rendered ineffective by the digestive system if taken by mouth.

History

Vosoritide was developed by BioMarin Pharmaceutical and got orphan drug status in the US as well as the European Union.[5][7][13][9]

The safety and efficacy of vosoritide in improving growth were evaluated in a year-long, double-blind, placebo-controlled, phase III study in participants five years and older with achondroplasia who have open epiphyses.[4] In the study, 121 participants were randomly assigned to receive either vosoritide injections under the skin or a placebo.[4] Researchers measured the participants' annualized growth velocity, or rate of height growth, at the end of the year.[4] Participants who received vosoritide grew an average 1.57 centimeters taller compared to those who received a placebo.[4] The US Food and Drug Administration (FDA) granted the approval of Voxzogo to BioMarin.[4]

Society and culture

Controversy

Some people with achondroplasia, as well as parents of children with this condition, have reacted to vosoritide's study results by saying that dwarfism is not a disease and consequently does not need treatment.[14]

Research

Vosoritide has resulted in increased growth in a clinical trial with 26 children. The ten children receiving the highest dose grew 6.1 centimetres (2.4 in) in six months, compared to 4.0 centimetres (1.6 in) in the six months before the treatment (p=0.01).[15] The body proportions, more specifically the ratio of leg length to upper body length – which is lower in achondroplasia patients than in the average population – was not improved by vosoritide, but not worsened either.[16]>[17]

References

  1. ↑ 1.0 1.1 "Voxzogo APMDS". 4 August 2022. https://www.tga.gov.au/resources/auspmd/voxzogo. 
  2. ↑ "Updates to the Prescribing Medicines in Pregnancy database". 21 December 2022. https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database. 
  3. ↑ 3.0 3.1 3.2 3.3 "Voxzogo 0.4MG- vosoritide kit Voxzogo 0.56MG- vosoritide kit Voxzogo 1.2MG- vosoritide kit". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=228e8560-04a4-4bb1-a81f-29531a9e4d27. 
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 "FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism". U.S. Food and Drug Administration (FDA) (Press release). 19 November 2021. Archived from the original on 19 November 2021. Retrieved 19 November 2021. This article incorporates text from this source, which is in the public domain.
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 "Voxzogo EPAR". 23 June 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo.  Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. ↑ "Voxzogo Product information". https://ec.europa.eu/health/documents/community-register/html/h1577.htm. 
  7. ↑ 7.0 7.1 "European Commission Approves BioMarin's Voxzogo (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close" (Press release). BioMarin Pharmaceutical. 27 August 2021. Archived from the original on 28 August 2021. Retrieved 9 September 2021 – via PR Newswire.
  8. ↑ "BioMarin Receives FDA Approval for Voxzogo (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates" (Press release). BioMarin Pharmaceutical. 19 November 2021. Archived from the original on 6 August 2022. Retrieved 19 November 2021 – via PR Newswire.
  9. ↑ 9.0 9.1 (PDF) Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (Report). 13 May 2022. https://www.fda.gov/media/155227/download. Retrieved 22 January 2023.  This article incorporates text from this source, which is in the public domain.
  10. ↑ 10.0 10.1 10.2 "Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia". American Journal of Human Genetics 91 (6): 1108–14. December 2012. doi:10.1016/j.ajhg.2012.10.014. PMID 23200862. 
  11. ↑ Clinical trial number NCT02055157 for "A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia (ACH)" at ClinicalTrials.gov
  12. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN): List 112". WHO Drug Information 28 (4): 539. 2014. https://www.who.int/medicines/publications/druginformation/PL112-final.pdf. 
  13. ↑ "Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia" (Press release). BioMarin Pharmaceutical. 2 November 2020. Archived from the original on 10 September 2021. Retrieved 9 September 2021 – via PR Newswire.
  14. ↑ Pollack, Andrew (17 June 2015). "Drug Accelerated Growth in Children With Dwarfism, Pharmaceutical Firm Says". The New York Times. https://www.nytimes.com/2015/06/18/business/drug-accelerated-growth-in-children-with-dwarfism-pharmaceutical-firm-says.html. 
  15. ↑ "BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study". BioMarin. 17 June 2015. http://investors.bmrn.com/releasedetail.cfm?ReleaseID=918431. 
  16. ↑ "Neue Wirkstoffe – Vosoritid" (in German). Österreichische Apothekerzeitung (14/2015): 28. 6 July 2015. 
  17. ↑ "Vosoritid" (in de). Arznei-News.de. 20 June 2015. http://arznei-news.de/vosoritid. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Vosoritide&oldid=2966303"